Bridgeway Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$199K Buy
+58,993
New +$267K ﹤0.01% 1021
2026
Q2
– Sell
-13,400
Closed -$76.9K – 1283
2026
Q1
$76.9K Hold
13,400
– – ﹤0.01% 1157
2025
Q4
$133K Sell
13,400
-35,000
-72% -$319K ﹤0.01% 1088
2025
Q3
$321K Sell
48,400
-5,000
-9% -$24.2K 0.01% 907
2025
Q2
$215K Buy
53,400
+15,000
+39% +$49.3K 0.01% 946
2025
Q1
$133K Sell
38,400
-26,600
-41% -$118K ﹤0.01% 993
2024
Q4
$428K Buy
+65,000
New +$512K 0.01% 849

Other funds holding LXEO

Bridgeway Capital Management's LXEO Position: Q3 2026 in Review

Bridgeway Capital Management opened a new position in Lexeo Therapeutics (LXEO) in Q3 2026: 58,993 shares worth $199K. The stake represents ﹤0.01% of the portfolio and ranks #1021 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in LXEO as recently as Q1 2026.

Bridgeway Capital Management first reported a position in LXEO in Q4 2024 and has held it in 7 quarters since. The position peaked at $428K in Q4 2024. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Bridgeway Capital Management held 58,993 shares of Lexeo Therapeutics worth $199K as of Q3 2026.
  • Lexeo Therapeutics was a new Bridgeway Capital Management position in Q3 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1021 holding.
  • Bridgeway Capital Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Bridgeway Capital Management's Lexeo Therapeutics position peaked at $428K in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.